NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK

BACKGROUND: The objective was to evaluate the cost-effectiveness of NEPA, an oral fixed combination netupitant (NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with aprepitant and palonosetron (APPA) or palonosetron (PA) alone, to prevent chemotherapy-induced nausea and vomiting (CINV) in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Cawston, Helene, Bourhis, Francois, Eriksson, Jennifer, Ruffo, Pierfrancesco, D’Agostino, Paolo, Turini, Marco, Schwartzberg, Lee, McGuire, Alistair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Just Medical Media Limited 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378057/
https://www.ncbi.nlm.nih.gov/pubmed/28392826
http://dx.doi.org/10.7573/dic.212298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378057/
https://www.ncbi.nlm.nih.gov/pubmed/28392826
http://dx.doi.org/10.7573/dic.212298

Ejemplares similares